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Abstract 
Positron emission tomography (PET) imaging reporter genes (IRGs) and PET reporter probes 
(PRPs) are amongst the most valuable tools for gene and cell therapy. PET IRGs/PRPs can be 
used to non-invasively monitor all aspects of the kinetics of therapeutic transgenes and cells in 
all types of living mammals. This technology is generalizable and can allow long-term kinetics 
monitoring. In gene therapy, PET IRGs/PRPs can be used for whole-body imaging of thera-
peutic transgene expression, monitoring variations in the magnitude of transgene expression 
over time. In cell or cellular gene therapy, PET IRGs/PRPs can be used for whole-body 
monitoring of therapeutic cell locations, quantity at all locations, survival and proliferation 
over time and also possibly changes in characteristics or function over time. In this review, we 
have classified PET IRGs/PRPs into two groups based on the source from which they were 
derived: human or non-human. This classification addresses the important concern of po-
tential immunogenicity in humans, which is important for expansion of PET IRG imaging in 
clinical trials. We have then discussed the application of this technology in gene/cell therapy 
and described its use in these fields, including a summary of using PET IRGs/PRPs in gene and 
cell therapy clinical trials. This review concludes with a discussion of the future direction of 
PET IRGs/PRPs and recommends cell and gene therapists collaborate with molecular imaging 
experts early in their investigations to choose a PET IRG/PRP system suitable for progression 
into clinical trials. 
Key  words:  Positron  Emission  Tomography,  PET  Imaging  Reporter  Genes,  Therapeutic 
Transgenes, Genetically Modified Therapeutic Cells, Imaging Therapeutic Transgenes or Cells 
Introduction 
The fields of gene and cellular gene therapy have 
seen considerable progress over the past two decades 
with  both  viral  and  non-viral  transgene  delivery 
techniques advancing into clinical trials.1-3 Yet, there is 
only  one  gene  therapy  drug,  Gendicine  (Shenzhen 
SiBiono  Gene  Technologies  Co.  (SiBiono)  Ltd.)  ap-
proved  for  commercialization  in  China.  Concerns 
about safety (mutagenesis, immune reactions, etc…) 
and limited demonstrations of efficacy are slowing the 
advancement  of  gene  therapeutics  into  approved 
drugs. Monitoring the kinetics of administered ther-
apeutic  transgenes,  especially  during  clinical  trials 
would help in the optimization of both gene thera-
peutic agents and their administration protocols. 
In  gene  therapy  we  monitor  kinetics  by  deter-
mining  the  sites,  magnitude  and  time  variation  of 
therapeutic  transgene  expression  in  vivo  following 
administration. In cellular gene therapy kinetics are 
Ivyspring  
International Publisher   Theranostics 2012, 2(4) 
 
http://www.thno.org 
375 
monitored  by  tracking  the  locations  of  genetically 
engineered therapeutic cells, measuring their quantity 
at  each  location  and  determining  changes  in  their 
characteristics at various time points in vivo following 
their  administration.  These  kinetic  studies  will  also 
provide  information  about  proliferation  and  persis-
tence of genetically engineered therapeutic cells. Ide-
ally, kinetic studies should be non-invasive, to avoid 
potential complications of surgical procedures or tis-
sue sampling. In addition, whole-body kinetics mon-
itoring would be ideal. 
Molecular imaging reporter genes (IRGs) offer a 
generalizable  method  for  non-invasive,  whole-body 
therapeutic transgene/cell kinetics monitoring  in vi-
vo.4-10 Although IRGs are  available for  fluorescence, 
bioluminescence  and  magnetic  resonance  imaging, 
radionuclide  based  IRGs  are  currently  the  only  re-
porter  genes  for  non-invasive  imaging  of  transgene 
expression in humans.7,11-17  
Positron  emission  tomography  (PET)  takes  ad-
vantage  of  coincidence  detection  of  two  511  KeV 
gamma rays, emitted at an angle of about 1800 when 
positrons collide with electrons (Figure 1). This anni-
hilation event allows precise detection of the location 
of  positron  radiolabeled  molecules  and  uniquely 
permits the quantification of molecular events in vivo. 
Furthermore,  the  short  half-life  of  fluorine-18,  the 
radioisotope that is commonly used for labeling PET 
tracers allows for repetitive imaging, which in turn 
permits studying kinetics in vivo. In this review, we 
will focus on PET IRGs and their applications in gene 
and cellular gene therapies. 
PET imaging probes reveal the presence of their 
target by accumulating on the surface or inside the 
cells containing the target while clearing from other 
cells. PET reporter probes (PRPs) image the expres-
sion of their PET IRGs in the same manner, by accu-
mulating on the surface or inside the cells expressing 
the PET IRGs. Therefore, traditionally, PET IRG/PRP 
systems have been classified into three groups based 
on the way the protein product of the PET IRG inter-
acts with its PRP to cause its accumulation: (i) PET 
IRGs encoding enzymes  that phosphorylate specific 
PRPs  which  causes  their  intracellular  entrapment 
(Figure 2A); (ii) PET IRGs encoding protein receptors 
that can be bound by specific PRPs (Figure 2B); (iii) 
PET IRGs encoding cell membrane transporters that 
facilitate the flow and accumulation of specific PRPs 
into cells (Figure 2C).  
 
 
 
Fig. 1. Mechanism of positron emission tomography (PET) imaging. PET is a molecular imaging modality useful for pre-clinical 
and clinical imaging of molecular events in living subjects. PET imaging involves a positron emitting radioisotope labeled imaging probe and 
instrumentation that can detect in a coincidence manner the radiation emitted when positrons from the imaging probe collide with nearby 
electrons. In this manner, PET cameras acquire data about the precise location of imaging probes inside the body of a living subject and the 
amount of imaging probe accumulated at every site at any given time. PET imaging probes usually accumulate at a site through binding to 
receptor molecules, interaction with an enzyme, or a cellular transport mechanism. Theranostics 2012, 2(4) 
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Fig. 2. Traditional classification of PET IRG/PRP systems based on their mechanism of action. A) The reporter gene en-
codes an enzyme that catalyzes chemical transformation of the reporter probe, thereby the reporter probes gets trapped within cells 
expressing the reporter gene. B) The reporter gene encodes a protein receptor that can be specifically bound by a radiolabeled ligand 
reporter probe. C) The reporter gene encodes a protein transporter that transports the radionuclide reporter probe into the cells 
expressing the reporter gene. Illustrations reprinted from review article by Penuelas et al.12  Theranostics 2012, 2(4) 
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An unresolved issue of using IRGs to monitor 
therapeutic transgene or cell kinetics is immunogen-
icity of IRGs. As illustrated in figure 3, immunogenic-
ity  of  a  PET  IRG  can  be  detrimental  to  adoptively 
transferred therapeutic cells expressing it. Therefore, 
most  recently,  efforts  towards  developing  human 
derived PET IRGs are being intensified. Current PET 
IRG and PRP systems can be grouped into a) those 
derived from viruses and other non-human sources 
that are likely to be rejected by the human immune 
system, and b) human gene-based PET IRGs that are 
less likely to be rejected by the human immune sys-
tem. Table 1 suggests characteristics of a PET reporter 
gene/probe  system  that  would  be  best  suited  for 
clinical  gene  and  cell  therapy  applications.  Table  2 
lists the PET IRG/PRP systems that have thus far been 
studied.  
 
 
 
 
Fig. 3. The mechanism and consequences of PRG immunogenicity. The PRG is transcribed and translated in genetically engi-
neered therapeutic cells; peptides derived from the PRG are displayed on the cell surface in the context of MHC class I molecules. If these 
peptides have never been encountered by the host immune system (i.e., they are ‘foreign’), they are detected by CD8+ T cells, which then 
kill the therapeutic cells, leading to treatment failure. In contrast, if the PRG is sufficiently similar or identical to a gene normally expressed 
by the host (‘self’ rather than ‘foreign’) it is less likely that the therapeutic cells will be detected as ‘foreign’ and eliminated. 
 
 
 
 
Table 1: Characteristics of an ideal PET reporter gene (PRG)/probe (PRP) system for clinical gene and cell therapy imaging 
applications. 
1. The protein encoded by the PRG does not cause an immune reaction. Ideally the PRG is a human-derived gene that is not expressed. 
2. The protein encoded by the PRG is inert. It does not cause cytotoxicity by itself and after interaction with the trace amounts of the PRP. It 
also does not alter the normal or intended functions of the cells, having no effect on the cells’ characteristics. 
3. Image signal correlates well with the levels of PRG mRNA and protein in tissues of the living subject. 
4. For transgene delivery applications, the size of the PRG is small enough to fit into the appropriate transgene delivery vehicle. 
5. For cell therapy applications, the PRG can also serve as a safety gene, enabling suicide elimination of therapeutic cells if they are causing 
severe adverse effects. 
6. PRP can be synthesized rapidly enough before significant decay has occurred and with high specific activity. 
7. The PRP is accumulated only by the cells expressing the PRG. The PRP is cleared rapidly from organs or tissues that do not contain the 
cells expressing the PRG. The PRP does not attach to and rapidly effluxes from cells not expressing the PRG.  
8. The PRP is stable and the signal emitting moiety of the PRP is not cleaved before reaching target cells and while accumulated by the PRG 
expressing cells. Excess PRP is cleared or metabolized and cleared rapidly to reduce background. 
9. PRP or its metabolites are not toxic at 100X the required administered doses. This is unlikely to be an issue for PET tracers. 
10. The PRP has ideal dosimetry in humans, allowing injection of sufficient doses, multiple times within a year without exceeding 5 REM to 
any organ or 3 REM to sensitive organs, such as bone marrow, lens of the eyes, testicles and ovaries. 
11. PRP can cross physiological barriers to reach the target PRG expressing cells. For example, an ideal PRP would cross the blood brain 
barrier. 
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Table 2: PET reporter gene/probe systems 
Reporter Gene  Reporter Probe    Advantages  Disadvantages 
1. Reporter Genes Potentially Immunogenic in Humans 
Herpes Simplex Virus thy-
midine kinase 
(HSV1-tk) and mutants: 
HSV1-sr39tk, 
HSV1-A167Ysr39tk, 
HSV1-A167Ytk, 
HSV1-A168Htk,  
HSV1-R176Qtk, Destabi-
lized HSV1-tk 
[18F]FHBG 
[18F]FEAU 
[124I]FIAU 
1. Relatively high sensitivity 
2. Most validated PET reporter 
gene/probe system 
3. Absence of reporter gene in normal 
mammalian cells 
4. Several PRPs with good pharmaco-
kinetics 
5. FDA IND approved PRP 
([18F]FHBG) 
6. Dual purpose IRG and suicide gene 
1. Available probes don’t cross the BBB 
2. High activity in organs involved in 
clearance 
3. Deiodination of the radio-iodine la-
beled probes 
4. Possible perturbation of cell character-
istics like all other reporter genes 
Varicella-Zoster Virus 
Thymidine Kinase (VZV-tk) 
[18F or 11C]BCNA  Probes specific for VZV-tk  and not 
HSV1-tk 
BCNA did not cross BBB 
LacZ  [11C] β-galactosyl 
triazoles 
  Probes not specific for LacZ 
2. Reporter Genes Less Likely to be Immunogenic in Humans 
Modified human mito-
chondrial thymidine kinase 
(hmTK2) and optimized 
mutants  
[18F]FEAU 
[124I]FIAU, [18F]L-FMAU 
1. Dual purpose RG and suicide gene 
2. Available RPs with good pharma-
cokinetics 
3. May be used in patients receiving 
Penciclovir 
1. Currently, lower sensitivity than 
HSV1-tk and mutants 
2. Available probes don’t cross the BBB 
3. High activity in organs involved in 
clearance 
4. Deiodination of the radio-iodine la-
beled probes 
5. Possible perturbation of cell character-
istics like all other reporter genes  
Truncated mutant deox-
ycytidine kinase 
(h∆dCKDM) 
 
[18F]FEAU 
 
1. May be used in patients receiving 
Penciclovir 
1. Probe doesn’t cross the BBB 
2. Possible perturbation of cell character-
istics like all other reporter genes 
Dopamine 2 Receptor (D2R) 
Mutant D2R 
[18F]FESP 
Also potentially: 
[11C]Raclopride 
[11C]N-methylspiperone 
 
1. Non-mutated human gene is not 
immunogenic 
2. [18F]FESP can be used in humans 
and has good pharmacokinetics 
3. Probe can cross BBB  
4. Binding of FESP to mutant D2R does 
not cause signal transduction 
1. High background in Pituatory and 
Striatum 
2. Long wait time for [18F]FESP clearance  
 
Human estrogen receptor α 
ligand binding domain 
(hERL) 
[18F]FES  1. Probe can cross BBB 
2. Probe used in clinic  
3. hERL lacks activity as a transcrip-
tion factor 
1. Estrogen receptor is over-expressed in 
uterus, ovaries, mammary gland and 
breast cancer cells  
Human somatostatin re-
ceptor subtype 2 (hSSTr2) 
68Ga-DOTATOC  1. The PRP has good pharmacokinet-
ics and has already undergone clinical 
testing 
1. Somatostatin binding to hSSTr2 can 
cause cell signaling; hence expression 
may perturb cell characteristics 
2. Some tumors and tissues express 
hSSTr2 
Recombinant human car-
cinoembryonic antigen 
(CEA) 
Iodine-124 labeled An-
ti-CEA scFv-Fc 
H310A antibody frag-
ment 
1. Not expressed in normal adult hu-
man cells, except for colon lumen  
1. Dehalogenation of probe 
2. Naturally overexpressed in carcinomas 
3. Long half-life makes unsuitable for 
dynamic imaging 
4. Probe cannot image in CNS 
Engineered antibody frag-
ments: DAbR1 
86Y-AABD  1. Humanized IRG 
2. High sensitivity 
1. Possibly immunogenic 
2. 86Y is not a good PET radioisotope 
Humanized membrane 
anchored anti-polyethylene 
glycol (PEG) 
124I-PEG-SHPP  1. A universal IRG allowing imaging 
by PET, MRI and optical probes 
2. PEG is non-toxic and FDA ap-
proved 
1. Long half-life of iodine does not allow 
dynamic imaging of molecular events. 
2. Potential deiodination. 
Sodium Iodide Symporter 
(NIS) 
124I 
 
1. Lack of immune reaction 
2. Easy to obtain probes 
3. Dual purpose as a reporter gene and 
a therapeutic transgene 
1. Naturally expressed in thyroid, stom-
ach, salivary glands, mammary glands, 
and sometimes breast cells 
2. Probes are not trapped and can efflux, 
short imaging window 
Human norepinephrine 
transporter (hNET) 
[124I]MIBG  1. Probes clinically used  1. High normal tissue background, since 
hNET is expressed in many normal tis-
sues  
2. Induced hNET expression will likely 
change cell biological function 
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PET Reporter Genes Derived From Viruses 
and Other Non-Human Sources 
Herpes  simplex  virus  1  thymidine  kinase 
(HSV1-tk)  and  its  mutant  derivatives  have  thus  far 
been the most extensively studied and applied PET 
IRGs. These PET IRGs encode enzymes that catalyze 
phosphorylation  reactions  causing  entrapment  of 
their probes inside cells expressing them (Figure 2A). 
The specific PRPs for these PET IRGs are poor sub-
strates for mammalian thymidine kinase 1; hence they 
will  not  be  trapped  within  cells  that  don’t  express 
HSV1-tk or its mutants. Enzyme based PET IRGs have 
high  sensitivity  because  each  enzyme  can  catalyze 
many  phosphorylation  reactions  causing  signal  am-
plification.  However,  in  PET,  target  to  background 
activity  ratios  determine  the  true  sensitivity  of  the 
imaging assay. 
Over the last 15 years, mutants of HSV1-tk have 
been created to increase sensitivity, reduce affinity for 
thymidine,  increase  affinity  for  some  PRPs  while 
eliminating affinity for other PRPs, and shorten the 
half-life  of  the  PET  IRGs.18-25  New  PRPs  have  been 
synthesized and evaluated to increase affinity for ei-
ther HSV1-tk or its mutants and reduce background 
activity in some organs such as liver or gut.26-33 Most 
of  these  PRPs  (such  as  for  instance,  [18F]FHBG  and 
[18F]FEAU) were labeled with fluorine-18, while some 
others (for instance [124I]FIAU) were labeled with Io-
dine-124).  Fluorine-18  has  a  short  half-life  of  ~  110 
minutes;  whereas  Iodine-124  has  a  long  half-life  of 
4.18 days. As an advantage, fluorine-18 labeled PRPs 
permit  imaging  on  two  consecutive  days  and  are 
more suitable for monitoring time variation of thera-
peutic  transgene  expression  or  therapeutic  cell  bio-
distribution than iodine-124 labeled probes. 
The clinical utility of HSV1-tk has been studied 
in both cancer gene therapy and cancer cellular gene 
therapy  trials.11,13-15,17  For  example,  the  PRP 
9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine 
([18F]FHBG)  has  successfully  detected  adenovirally 
delivered  HSV1-tk  during  suicide  gene  therapy  of 
hepatocellular cancer and cytolytic T cells expressing 
HSV1-tk  during  cell  therapy  of  glioblastoma.11,13 
[18F]FHBG  has  a  FDA  approved  IND  (IND#61,880) 
and a published protocol for performing [18F]FHBG 
PET scans in humans is available.17,34,35 
HSV1-tk  and  its  mutants  have  several  ad-
vantages for gene and cellular gene therapy applica-
tions.  Many  PET  and  single  photon  emission  com-
puterized  tomography  (SPECT)  reporter  probes  are 
available with suitable pharmacokinetics in rodents, 
pigs and humans. Several of the available PRPs ex-
hibit relatively low background activity in mamma-
lian cells and tissues (because they are poor substrates 
for mammalian TK1). They have multiple utilities as 
PET IRGs, suicide genes (i.e. genes that can activate 
pro-drugs and make them toxic to for instance cancer 
cells) and safety genes (can be used through their sui-
cide mechanism to eradicate therapeutic cells, if they 
cause  an  adverse  effect).36  In  addition,  these  en-
zyme/radionuclide  based  PET  IRG/PRP  systems 
have been validated for imaging of a variety of mo-
lecular  events,  non-invasively,  in  living  mammals, 
including humans.  
Nevertheless,  HSV1-tk  and  its  mutants  have 
shortcomings that limit their utility. One limitation is 
the  potential  immunogenicity  of  HSV1-tk  and  its 
mutants  that  limits  their  application  in  immu-
no-competent hosts. For example, an immune reaction 
to the protein products of these PET IRGs may cause 
pre-mature  elimination  of  the  therapeutic  cells  that 
are expressing them.37,38 Therefore, as discussed later 
in this review, human derived PET IRGs have been 
and are being developed to address these limitations.  
Another limitation is that the PRPs do not cross 
the blood brain barrier (BBB); hence they may not be 
useful in cases where therapeutic transgenes or cells 
are targeted to sites within the central nervous sys-
tem. For example, they may not be useful for moni-
toring the kinetics of therapeutic stem cells adminis-
tered  for  the  treatment  of  some  neurodegenerative 
disorders. Finally, improvements in imaging sensitiv-
ity  of  HSV1-tk,  its  mutants  and  other  PET  IRGs, 
would increase their utility in monitoring therapeutic 
transgene or cell kinetics. 
Two other PET IRGs of non-human origin, the 
Varicella-Zoster virus thymidine kinase (VZV-tk) and 
LacZ will likely encounter immunogenicity issues.39,40 
The VZV-tk PET IRG was developed with the hope 
that its  PRPs bicyclic nucleoside analogues (BCNA) 
could cross the BBB. However, this approach failed. 
The LacZ gene encodes the bacterial -Galactosidase 
(-Gal) enzyme, used as a reporter gene (RG) for in 
vitro  studies  with  chromogenic  and  fluorogenic  re-
porter probes and can also serve as a MRI reporter 
gene.41-43  However,  thus  far  all  PRPs  designed  for 
-Gal either do not cross cell membranes or are not 
specific.40 Therefore, amongst PET IRGs that do not 
have a human gene counterpart, HSV1-tk and its op-
timized  mutants  and  PRPs  still  represent  the  most 
useful PET IRG systems and they should serve as es-
sential tools for non-invasive pharmacokinetics mon-
itoring in both cell and gene therapy investigations. 
Potentially Non- Immunogenic PET-IRGs  
Immunogenicity  toward  proteins  encoded  by 
reporter genes can cause major problems in therapeu-Theranostics 2012, 2(4) 
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tic  transgene  or  cell  kinetics  monitoring  studies.  In 
gene therapy, it may shorten the duration of PET IRG 
expression.  In  cell  or  cellular  gene  therapy,  it  may 
cause pre-mature eradication of the therapeutic cells 
expressing the PET IRG. Several genes encoding pro-
tein  receptors,  transporters  and  kinases  have  been 
investigated  that  might  serve  as  non-immunogenic 
PET IRGs in humans. Alternatively, they might have 
mammalian species specific counterparts that can be 
used without rejection in immunocompetent animal 
research  models.44  These  include  dopamine  type  2 
receptor (D2R)45-48, human estrogen receptor  ligand 
binding domain (hERL)49,50, human type 2 somatosta-
tin  receptor  (hSSTr2)51-54,  recombinant  carcinoem-
bryonic  antigen  (CEA)55,  engineered  antibody  frag-
ments56, sodium  iodide  symporter (NIS)57-61,  human 
norepinephrine  transporter  (hNET)62,  human  mito-
chondrial  thymidine  kinase  type  2  (hmtk2)63,64,  mu-
tant  deoxycytidine  kinases65,  and  anti-polyethylene 
glycol (anti-PEG)66.  
However,  the  use  of  such  endogenous  human 
genes as PET IRGs has two potential problems: first, 
the PRP can also accumulate in cells that express the 
endogenous gene; second, the PET IRG would func-
tion like the endogenous gene and thus perturb the 
cells in which it is expressed. Moreover, it is still un-
known whether these PET IRG’s are immunogenic. To 
overcome  these  problems  mutations  have  been  in-
troduced to eliminate their function.47 Moreover, spe-
cific mutations have been designed to increase their 
detection sensitivity with specific PRPs.65 The human 
mitochondrial thymidine kinase 2 (hmtk2) represents 
an attractive candidate PET IRG. Even though hmtk2 
is  ubiquitously  expressed  in  the  mitochondria  of 
mammalian cells, it is not accessible to uracil nucleo-
side analogs that are its substrates. Therefore, a trun-
cated version of hmtk2 that can be expressed in the 
cytoplasm  can  serve  as  a  potentially 
non-immunogenic  PRG,  without  non-specific  accu-
mulation  of  its  PRPs.63  We  have  recently  designed 
double  mutants  of  truncated  hmtk2  that  combined 
with its PRP [18F]L-FMAU has a sensitivity compara-
ble to HSV1-tsr39tk/[18F]FHBG and reduced potential 
for cell perturbations or immunogenicity in humans.64 
Imaging Therapeutic Transgenes 
Therapeutic transgenes (TGs) are delivered into 
living organisms either directly or by using cells as 
vectors, which are then delivered into the mammal. 
There are two approaches to image the expression of 
TGs with PET: 1) If a specific PET probe is available, 
the mRNA or protein encoded by the TG can be de-
tected directly (Figure 4).36,67 2) If a specific PET probe 
is not available, the TG can be imaged indirectly by 
linking its expression to the expression of a PET IRG. 
The direct approach can be used to monitor expres-
sion  of  HSV1-tk  or  its  mutant  HSV1-sr39tk  during 
suicide gene therapy of cancer (Figure 5), since several 
specific  PET  probes  are  available  for  detecting  the 
enzymes encoded by these TGs/PET IRGs.13,14,25,36,68-71 
However,  specific  PET  probes  are  not  available  for 
most TGs and the costs  of developing  new  specific 
PET probes for each TG are high; hence the second 
approach of indirect imaging with PET IRGs may be 
more practical.  
 
 
 
Fig.  4.  Direct  imaging  of  a  therapeutic  transgene’s 
products with PET. Specific PET probes may be designed and 
developed  to  directly  image  the  messenger  ribonucleic  acids 
(mRNA) transcribed from a therapeutic transgene (TG) or the 
protein translated from its mRNA. Examples of potential mRNA 
PET imaging probes are radiolabeled antisense oligo-nucleotides 
(RASONs) or modifications of RASONs that are complementary 
to a specific region of an mRNA. There are also PET imaging 
probes that specifically detect a certain protein by binding to it or 
even detect the protein’s function. Examples are specific detection 
of  D2R  with  [18F]FESP  and  specific  detection  of  HSV1-sr39TK 
enzyme  activity  with  [18F]FHBG.  However,  developing  a  new 
specific PET probe to image the expression of any TG requires 
significant expenditure of resources and may not be practical.  Theranostics 2012, 2(4) 
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Fig. 5. Example of direct gene therapy monitoring with PET. Direct imaging of HSV1-sr39tk/GCV suicide gene therapy progress 
in C6 glioma xenografted immunodeficient mice. Four C6sr39 tumor xenografts were implanted subcutaneously on 4 sites of the nude 
mouse shown. All 4 tumors highly accumulated [18F]FHBG and [18F]FDG prior to starting GCV treatment (week 0). The mouse was 
administered daily IP injections of GCV (100 mg/kg) for two weeks, during which time period the tumors regressed (3 of them visually 
eradicated) and [18F]FHBG and [18F]FDG accumulation declined to background levels. The mouse was monitored up to three weeks after 
halting GCV treatment. The tumors re-grew, but only accumulated [18F]FHBG at background levels, despite robust ability to accumulate 
[18F]FDG. Reprinted from research article by Yaghoubi et al.36  Theranostics 2012, 2(4) 
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Fig. 6. Five genetic constructs enabling linkage of the expression of a therapeutic transgene to a PET imaging reporter 
transgene for indirect monitoring of the pharmacokinetics of the therapeutic transgene. Depending on the therapeutic 
transgene and the PET imaging reporter transgene used these constructs should allow expression of both transgenes in a correlated 
manner in a population of cells. Reprinted from figure 9.5 of a book chapter by Yaghoubi et al.9 
 
Five techniques are available for linking the ex-
pression of a transgene with a PET IRG for indirect 
imaging (Figure 6).46,72-80 The first, internal ribosomal 
entry site (IRES) based approach, involves the use of a 
single gene expression regulatory element to derive 
the  mRNA  expression  of  both  the  TG  and  the  PET 
IRG,  while  the  IRES  enables  the  translation  of  two 
separate proteins encoded by these transgenes. This 
approach has been validated and shown to yield cor-
related detection of the two proteins encoded by two 
IRGs that were linked in this manner.46,75,78,79,81 Usu-
ally, the TG is inserted upstream of the IRES and the 
PET IRG would be inserted downstream of the IRES 
to avoid attenuation of TG expression that may occur 
when a transgene is downstream the IRES. The dis-
advantage  is  that  attenuated  expression  of  the  PET 
IRG  would  reduce  detection  sensitivity.  This  ap-
proach is mostly suitable when one wants every sin-
gle cell that has the TG to also have the PET IRG, but 
wants to avoid any interference with the protein en-
coded by the TG. 
The second co-administration approach employs 
two  identical  transgene  delivery  vectors  containing 
identical  gene  expression  regulatory  elements,  one 
carrying the PET IRG and the other carrying the TG. 
This  simple  approach  works  because  PET  can  only 
image  a  population  of  cells  that  would  have  equal 
access  to  and  the  ability  to  take  up  both  transgene 
delivery vectors.73,76 In fact, Yaghoubi et al. initially 
demonstrated that when various equivalent titers of 
two identical adenoviruses, one carrying HSV1-sr39tk 
and the other carrying D2R, are co-delivered by in-
travenous injections into lateral tail veins of mice, a 
good  correlation  is  observed  between  activities  of 
[18F]FHBG  or  [18F]FESP  in  the  livers  of  these  mice 
(Figures 7A&B).73 This approach may be ideal when 
the vector containing the TG has already been vali-
dated and one does not want to alter the vector to also 
include  a  PET  IRG;  hence  one  would  produce  an 
identical  vector  containing  the  PET  IRG  to 
co-administer with the vector carrying the TG, there-
by tracking the kinetics of TG expression indirectly.  Theranostics 2012, 2(4) 
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Fig. 7. [18F]FESP and [18F]FHBG coronal images of (A) a Swiss Webster and (B) a Nude mouse at three different time 
points after co-injecting equivalent titers of Ad-CMV-HSV1-sr39tk and Ad-CMV-D2R intravenously. (A) 2.0 X 109 and (B) 
0.1 X 109 pfu of both Ad-CMV-D2R and Ad-CMV-HSV1-sr39tk were co-injected into the tail vein of a Swiss Webster mouse and a Nude 
mouse, respectively. The mice were then scanned for [18F]FESP and [18F]FHBG activity. For the [18F]FESP images times 1, 2, and 3 cor-
respond to 3, 10, and 24 days after the injection of the adenoviruses, respectively. For the [18F]FHBG images times 1, 2, and 3 correspond 
to 5, 12, and 26 days after the injection of the adenoviruses, respectively. The images are scaled for injected dose. These mice were 
representatives of a larger data set. Reprinted from research article by Yaghoubi et al.73 Theranostics 2012, 2(4) 
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The third, a fusion gene approach involves in-
serting the TG and IRG next to each other, regulated 
by  a  single  promoter,  such  that  a  single  encoded 
mRNA  and  fusion  protein  contains  the  product  of 
both transgenes. Interestingly, this technique has not 
yet been evaluated for imaging a TG, using PET IRGs, 
but  lead  to  the  development  of  multimodality  IRG 
constructs.82-88 The main problem with this approach 
is that the quaternary structure of the fusion protein 
may significantly alter the function of the protein en-
coded by the TG and significantly reduce detection 
sensitivity  of  the  protein  encoded  by  the  PET-IRG. 
Therefore, this approach may be ideal if lack of pro-
tein function alteration can be confirmed, because it 
may yield the best correlation between the expression 
of TG and PET IRG.  
The forth, dual promoter, approach involves in-
serting  both  the  TG  and  the  PET  IRG  on  the  same 
construct each having its own separate but identical 
promoter.89  This  approach  also  ensures  single  cell 
co-delivery and translation of separate proteins from 
the mRNAs encoded by the PET IRG and the TG.  
The fifth, bidirectional transcriptional approach 
involves inserting the RG and TG on opposite sides of 
a  bidirectional  regulatory  element,  each  having  its 
own separate but identical minimal promoter.77,80 This 
approach is most suitable when transgene expression 
needs to be up or down regulated at different time 
points. For a detailed discussion of advantages and 
disadvantages of each approach we refer the reader to 
a book chapter by Yaghoubi and Gambhir.9 
Imaging Genetically Modified Therapeutic 
Cells 
Adoptive  cellular  gene  therapy  is  a  promising 
approach for treating a variety of diseases, including 
neurodegenerative,  cardiovascular  and  autoimmune 
disorders as well as cancer.90-93 Targeted therapeutic 
cells (TCs) are injected into patients to restore normal 
organ  function  in  degenerative  diseases,  eliminate 
cancer cells, or correct a system malfunction in other 
diseases. Selection of appropriate cells, optimization 
of the cells to perform a specific therapeutic function 
and determination of an appropriate administration 
route and cell dose are necessary to achieve the de-
sired therapeutic effect.  
To  successfully  implement  new  cell  therapy 
protocols,  non-invasive  techniques  are  needed  for 
studying whole-body kinetics of TCs. Such monitor-
ing  would  provide  information  regarding  presence, 
location, quantity, proliferation, survival and status of 
TCs in animals or patients at any desired time-point 
following administration of TCs. This expanded type 
of  kinetic  analysis  is  impossible  with  conventional 
methods  that  require  euthanization  of  research  ani-
mals,  or  conventional  clinical  methods  that  require 
collection of multiple sequential biopsy samples from 
humans. Molecular imaging of TCs pre-labeled with 
imaging probes is insufficient as it will not yield in-
formation about TC survival, proliferation and change 
in characteristics (TC status).94-100 
Currently, only PET or SPECT IRGs are gener-
alizable tools for non-invasive imaging of all aspects 
of TC kinetics in mammals larger than rats.4,5,8,101 To 
use PET IRG imaging for monitoring the biodistribu-
tion, survival, proliferation and estimate quantities of 
TCs, these cells are first genetically engineered ex vivo 
to stably express a PET IRG under the control of a 
strong  constitutive  promoter.  Then,  at  desired  time 
points, following adoptive transfer of the genetically 
modified TCs, the PET reporter probe is injected and 
the recipient of the TCs is scanned with PET (Figure 
8). PET IRGs have been used to monitor the kinetics of 
various potential TCs, including immune cells, stem 
cells and pancreatic islets, in pre-clinical living animal 
models.102-123 Therefore, PET IRGs are valuable tools, 
one should use during development of cellular gene 
therapy  techniques  for  treatment  of  cancer  and  au-
toimmune, cardiovascular and neurological disorders. 
 
 
Fig. 8. PET IRG based imaging of the kinetics of a TC 
population. TCs are genetically engineered to stably express the 
PET IRG ex vivo. Following confirmation of PET IRG expression 
TCs are injected into the living subject. At any desired time point 
after TC administration the specific PRP is injected into the living 
subject and the subject is scanned for the biodistribution of the 
PRP. Quantitative PRP biodistribution analysis then allows studying 
the kinetics of the TCs in the subject. 
 
Clinical Translation of PET Reporter Gene 
Imaging 
 The sensitivity of PET IRGs is higher than that of Theranostics 2012, 2(4) 
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optical  IRGs  in  animals  larger  than  mice,  because 
gamma  rays  readily  penetrate  tissues.  Furthermore, 
their sensitivity is higher than that of MRI IRGs in all 
mammals. Therefore, they can be used for gene and 
cell therapy clinical applications. In fact, radionuclide 
based IRGs, have thus far been the only IRGs able to 
provide whole-body images of transgene expression 
in humans. 
Using [124I]FIAU, Jacob’s et al. successfully im-
aged non-virally administered HSV1-tk inside glioma 
tumor of a patient.15 In another study, Yaghoubi et al. 
reported the pharmacokinetics, safety and dosimetry 
of [18F]FHBG in healthy human volunteers.17 Subse-
quently, adenovirally delivered HSV1-tk was imaged 
in hepatocellular carcinoma.12,13 A specific [18F]FHBG 
signal was observed at tumor injection sites when > 
1012 particles of adenovirus had been injected intra-
tumorally. Interestingly, only patients who received > 
1012 particles and had been treated with valganciclovir 
had stable disease while those receiving lower particle 
numbers  did  not  respond  to  treatment.  In  2004,  all 
required  pre-clinical  safety,  dosimetry  and  toxicity 
studies for [18F]FHBG were completed and an inves-
tigational new drug (IND) approval was granted by 
US FDA.34 This enabled the first clinical trial  of re-
porter gene based cell imaging in patients with glio-
ma. In this study, the gliomas were first resected and a 
total  of  109  potentially  therapeutic  autologous  cyto-
lytic  T  cells  (CTLs)  that  stably  expressed  HSV1-tk 
were  then  injected  into  the  resection  cavity  over  a 
period of 5 weeks (Figure 9A). Following infusion of 
all the cells a whole-body [18F]FHBG PET scan was 
performed.  This  first  imaging  study  showed  above 
background [18F]FHBG signal at the site of cytolytic T 
cell infusions and revealed trafficking of these cells to 
a remote recurrent tumor in the patient’s corpus cal-
losum (Figure 9B).11 This study has set the stage for 
future studies, using [18F]FHBG PET for imaging bio-
distribution  of  genetically  engineered  therapeutic 
cells in patients and such clinical studies are planned 
at  multiple  medical  centers  in  the  United  States.  A 
published  peer-reviewed  protocol  for  imaging  hu-
mans with [18F]FHBG is available.35  
Future Directions 
A major goal for PET IRGs and their probes is 
their wide-spread adoption by academic and industry 
developers  of  various  cell  and  gene  therapy  ap-
proaches.  We  believe,  this  requires  close  and  early 
collaborations  between  molecular  imagers  and 
cell/gene therapists. This would afford a parallel ap-
proach starting with pre-clinical studies so that PET 
reporter gene imaging can be incorporated into the 
cell or gene therapy investigational new drug proto-
col. Early collaboration is also needed for optimizing 
the delivery of the PET IRG for the specific cell or gene 
therapy  approach.  Safe  and  stable  PET  reporter 
transgene delivery for clinical applications is a major 
hindrance to adoption and will be better addressed 
when molecular imagers and gene therapists collab-
orate early. Early collaboration may also help resolve 
another hindrance to clinical translation, which is ef-
ficient delivery  of PET IRGs into primary cells that 
cannot be cultured ex vivo for long periods of expan-
sions.  
The hope for not too distant future of this inval-
uable technology is exponential growth in its use in 
cell and gene therapy clinical trials. This is likely to 
happen  soon  as  additional  non-immunogenic  PET 
IRGs with high sensitivity probes become available. 
Improvements  to  the  currently  existing  PET  IRGs 
would also help broaden their use in cell and gene 
therapy  trials.  PRPs  with  better  pharmacokinetics, 
with reduced backgrounds and increased bioavaila-
bility would also enhance the application of PET IRG 
based  cell  and  transgene  imaging.  However,  again 
working early with IRG experts, gene and cell thera-
pists will be able to choose the most suitable currently 
available  PET  IRG/PRP  system  that  would  allow 
progression into clinical trials. 
A  new  molecular-genetic  imaging  industry  is 
emerging  with  the  aim  of  educating  therapeutics 
firms and regulatory agencies about the applications 
of imaging reporter genes and expanding their use in 
clinical  trials.  For  example,  CellSight  Technologies 
located in California, USA was founded for this mis-
sion.  A  world-wide  effort  is  underway,  in  North 
America,  Europe,  Southeast  Asia  and  Australia  to 
improve  PET  IRG  technologies  and  satisfy  require-
ments for getting them into clinical trials. 
Many  of  the  gene  and  cellular  gene  therapy 
treatments currently listed on clinical trials.gov would 
benefit from PET IRG based transgene or cell kinetics 
monitoring.  Of  course,  pre-clinical  imaging  studies 
would be required before incorporation of the imag-
ing studies in the clinical trials. Table 3 lists some of 
the treatments that are currently recruiting for clinical 
trials that would benefit from PET IRG based imag-
ing. In these studies PET-IRG based imaging would 
reveal  the  locations  of  genetically  engineered  cells 
administered for treatment and would inform early 
on whether appropriate targeting has occurred; hence 
enabling  prediction  of  potential  efficacy  or  adverse 
effects. As described in this review, PET IRG expres-
sion can also be linked to the expression of the thera-
peutic  transgenes,  which  would  enable  monitoring 
the locations, magnitude and duration of expression 
of the therapeutic transgenes. Indeed in some cases Theranostics 2012, 2(4) 
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linking is not even necessary. For example, some of 
the  trials  listed  involve  suicide  gene  therapy  with 
HSV1-tk  or  radiation  therapy  following  sodium  io-
dide symporter gene therapy. Both of these therapeu-
tic transgenes already have PRPs that can be used to 
image them during clinical trials. As the value of PET 
IRG  based  imaging  is  recognized  in  the  future,  we 
expect utilization of these tools in many gene and cell 
therapy trials. 
 
Fig. 9 (A). Description of the procedures involved in the preparation of genetically engineered CTLs and their infusion 
into the recurrent glioma tumor resection site. (B). MRI and PET over MRI superimposed brain images of a patient 
recieving genetically engineered cytolytic T cells expressing HSV1-tk for imaging and safety purposes. Images were ac-
quired approximately two hours after [18F]FHBG injection. The patient had a surgically resected tumor (1) in the right parietal lobe and a 
new non-resected tumor in the center (2), near corpus callosum of his brain. The infused cells had localized at the site of tumor 1 and also 
trafficked to tumor 2. [18F]FHBG activity is higher than the brain background at both sites. Background [18F]FHBG activity is low within the 
Central Nervous System due to its inability to cross the blood brain barrier. Background activity is relatively higher in all other tissues. 
Activity can also be observed in the meninges. The tumor 1/meninges and tumor 2/meninges [18F]FHBG activity ratio in this patient was 
1.75 and 1.57, respectively. Whereas the average resected tumor site/meninges and intact tumor site to meninges [18F]FHBG activity ratio 
in control patients was 0.86 and 0.44, respectively. Figure 9A is a reprint of figure 13.9 from a book chapter by Penuelas et al.7 and Figure 
9B is a reprint of figure 1 from a case study report by Yaghoubi et al.11 Theranostics 2012, 2(4) 
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Table 3: Currently recruiting gene/cellular gene therapy clinical trials that would benefit from PET IRG based kinetics 
monitoring in treatment development. 
Gene/Cell Therapeutic Agent  Treatment Target 
Suicide Gene/Prodrugs: 
Herpes Simplex virus type 1 thymidine kinase/Ganciclovir or Penciclovir 
Sodium Iodine Symporter/Radio-iodine therapy 
Purine Nucleoside Phosphosrylase/Fludarabine phosphate 
Cytosine deaminase transgene/5-Fluorouracil 
 
Cancer 
 
Eradication of malfunctioning cells administered into 
patients 
Adoptive cellular immune-gene therapy: 
Genetically engineered T cells 
Genetically engineered natural killer cells 
Cancer 
AIDS 
Cell based vaccines  Cancer 
CD34+ cells expressing -globin  Sickle cell anemia and -Thalassemia 
Fanconi anemia complementation group A gene expressing hematopoietic stem 
cells  
Fanconi Anemia 
Antiangiogenic Therapy: 
Endostatin transgene 
Anti-VEGF receptor CD8+ lymphocytes 
Cancer 
Human endothelial nitric oxide synthase transgene  Pulmonary Hypertension 
Adenosine deaminase transgene  Severe Combined Immunodeficiency 
Gp91 transgene  Chronic Granulomatous Disease 
Hematopoietic stem cells lentivirally transduced to express the Wiskott-Aldrich 
syndrome protein encoding transgene 
Wiskott-Aldrich syndrome 
Adenylyl cyclase type 6 transgene  Congestive Heart Failure 
Nerve growth factor transgenes  Alzheimer Disease 
Neurturin transgene  Parkinson’s Disease 
Messenchymal stem cells  Kidney transplant recipients 
Cancer patients with kidney failure 
Chronic graft vs host disease 
Osteoarthritis 
Allogeneic stem cells   Severe Aplastic Anemia 
Autologous epidermal sheets engineered to express collagen type VII transgene  Recessive Dystrophic Epidermolysis Bullosa 
VEGF transgene  Critical Limb Ischemia 
Stem cell therapy  Cardiovascular diseases 
Multiple Sclerosis 
Hereditary Ataxias 
Myasthenia Gravis 
Type 1&2 Diabetes Mellitus 
Liver Cirrhosis 
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